MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

Kodu・Aktsiate loetelu・Fulgent Genetics Inc

Fulgent Genetics Inc

Suletud

SektorTervishoid

27.9 0.22

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.9

Max

27.9

Põhinäitajad
By Trading Economics
Sissetulek	12M -6.8M
Müük	2.3M 84M
Kasumimarginaal	-8.12
Töötajad	1,313
EBITDA	15M -77K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+16.53% upside

Turustatistika
By TradingEconomics
Turukapital	77M 784M
Eelmine avamishind	27.68
Eelmine sulgemishind	27.9

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

17.32 / 19.04 Toetus ja vastupanu

Fulgent Genetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. jaan 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15. jaan 2026, 00:00 UTC

Tulu

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14. jaan 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14. jaan 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14. jaan 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14. jaan 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14. jaan 2026, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14. jaan 2026, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14. jaan 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14. jaan 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14. jaan 2026, 22:09 UTC

Tulu

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14. jaan 2026, 22:08 UTC

Tulu

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14. jaan 2026, 21:53 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14. jaan 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Announces Positive Profit Alert for 2025

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Citigroup Acting as Financial Advisor to WuXi XDC

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Aims to Keep Listing Status of BioDlink

14. jaan 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

14. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. jaan 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14. jaan 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

WuXi XDC Makes Cash Offer for BioDlink International

14. jaan 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14. jaan 2026, 20:30 UTC

Market Talk

Tulu

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14. jaan 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14. jaan 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14. jaan 2026, 19:06 UTC

Market Talk

Tulu

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fulgent Genetics Inc Prognoos

Hinnasiht

By TipRanks

16.53% tõus

12 kuu keskmine prognoos

Keskmine 32.5 USD 16.53%

Kõrge 35 USD

Madal 30 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Fulgent Genetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Fulgent Genetics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

17.32 / 19.04Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

The bullish and bearish events are balanced.

Finantsandmed

Ettevõttest Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.